三家公司CEO参议院听证会 - 三家公司的CEO将在参议院听证会上就美国高昂处方药价格发表证词[4] - 三家公司生产的药物在美国销售价格昂贵，引起了参议院的关注[7][9] - 三种药物将成为第一轮医疗保险药物价格谈判的对象，旨在使昂贵的药物更加负担得起[10]

BALA CYNWYD, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. AVROBIO, Inc. (Nasdaq – AVRO) Under the terms of the agreement, AVROBIO will merge with Tectonic Therapeutic, Inc. ("Tectonic"). In the deal, pre-Merger AVROBIO shareholders ...

Wall Street analysts forecast that Bristol Myers Squibb (BMY) will report quarterly earnings of $1.56 per share in its upcoming release, pointing to a year-over-year decline of 14.3%. It is anticipated that revenues will amount to $11.11 billion, exhibiting a decline of 2.6% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 11.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their i ...

PALM BEACH, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Recent reports show that the Multiple myeloma Diagnostic market will continue to grow in the next several years. Multiple myeloma is a type of plasma cell cancer. Normal plasma cells are recognized as an important component of the immune system. The immune system is made up of various types of cells that work together to fight infections and other diseases. The main types of white blood cells in the immune system are lympho ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced three regulatory acceptances from the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) for Breyanzi® (lisocabtagene maraleucel). In the U.S., the FDA has accepted the company’s two supplemental Biologics License Applications (sBLA) for Breyanzi to expand into new indications to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) and rela ...

The latest trading session saw Bristol Myers Squibb (BMY) ending at $49.87, denoting a +0.34% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.76%. On the other hand, the Dow registered a gain of 0.59%, and the technology-centric Nasdaq increased by 1.12%.Coming into today, shares of the biopharmaceutical company had lost 3.14% in the past month. In that same time, the Medical sector gained 1.57%, while the S&P 500 gained 2.5%.The investment community w ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of data from the Phase 3 CheckMate -67T trial, evaluating the subcutaneous formulation of Opdivo (nivolumab) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) (herein referred to as “subcutaneous nivolumab”) compared to intravenous (IV) Opdivo in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy, demonstr ...

Healthcare stocks trudged through what was a terrible 2023 for the sector. While the S&P 500 rose by 24% during 2023, the healthcare sector managed paltry returns of 0.3%. Yet, hope springs eternal, particularly within the stock market, and investors are increasingly vocalizing their expectations for a 2024 rebound. Share prices throughout the sector remain muted, providing many targets for those hoping to capitalize on what they see as overly low valuations.Bargain hunters will have many choices throughout ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization approval of Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibod ...

Bristol-Myers Squibb Company (BMY) is scheduled to report fourth-quarter 2023 results on Feb 2, before market open.The company’s shares have lost 20.7% in the past six months compared with the industry's 0.3% growth.Image Source: Zacks Investment ResearchBristol-Myers beat earnings estimates in three of the last four quarters and missed once, the average surprise being 2.89%. In the previously reported quarter, the company beat estimates by 13.64%.Factors at PlayTotal revenues in the fourth quarter are like ...